Alterações farmacocinéticas de antimicrobianos em situações especiais: uma revisão narrativa
DOI:
https://doi.org/10.24220/2318-0897v27n3a4014Palavras-chave:
nti-infecciosos. Farmacocinética. Infecções.Resumo
Até o ano de 1940, as doenças infecciosas eram uma das principais causas de morte no Brasil. Atualmente, apesar de um grande declínio, a mortalidade ainda é elevada em relação a países desenvolvidos e a outros países da América Latina. Dessa maneira, o objetivo do presente trabalho foi relatar as alterações fi siológicas em condições específi cas, as consequências na farmacocinética dos antimicrobianos e ainda o impacto do ajuste de dose em tais situações. Realizou-se uma revisão narrativa de artigos publicados sobre a utilização de antimicrobianos nas seguintes situações: doença crítica e sepse, alcoolismo, tabagismo, extremos de idade, obesidade, nutrientes, polimorfismo genético, gravidez e lactação, insuficiência cardíaca, insuficiência hepática e renal. Observou-se que as alterações fisiológicas em tais situações afetam a farmacocinética dos antimicrobianos, modificando os processos de absorção, distribuição, metabolismo e excreção, os quais dependem muitas vezes da natureza do fármaco, podendo requerer ajuste de dose. Pôde-se concluir que as alterações observadas reduzem a precisão de uma dose terapêutica eficaz, evidenciando, dessa maneira, a importância do ajuste de dose.
Downloads
Referências
Araújo JD. Polarização epidemiológica no Brasil.
Epidemiol Serv Saúde. 2012;21(4):533-8.
Abrantes PM, Magalhães SMS, Acúrcio FA, Sakurai
E. A qualidade da prescrição de antimicrobianos em
ambulatórios públicos da Secretaria Municipal de
Saúde de Belo Horizonte, MG. Ciênc Saúde Coletiva.
;13:711-20.
Carneiro M, Ferraz T, Bueno M, Koch BE, Foresti C,
Lena VF, et al. O uso de antimicrobianos em um hospital
de ensino: uma breve avaliação. Rev Assoc Med Bras.
;57(4):421-4.
Pina E, Ferreira E, Marques A, Matos B. Infecções
associadas aos cuidados de saúde e segurança do
doente. Rev Port Saúde Pública. 2010;10:27-39.
Lima MEL, Andrade D, Hass VJ. Avaliação prospectiva
da ocorrência de infecção em pacientes críticos de
Unidade de Terapia Intensiva. Rev Bras Ter Intensiva.
;19(3):342-7.
Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic
drug monitoring of antimicrobials. Br J Clin Pharmacol.
;73(1):27-36.
Buffé C, Araújo BV, Dalla Costa T. Parâmetros farmacocinéticos e farmacodinâmicos na otimização de
terapias antimicrobianas. Cad Farm. 2001;17(2):97-109.
Vicent JL, Bassetti M, François B, Karam G, Chastre J,
Torres A, et al. Advances in antibiotic therapy in the
critically ill. Crit Care. 2016;20(133):1-13.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM,
Knaus WA, et al. Definitions for sepsis and organ
failure and guidelines for the use of innovative
therapies in sepsis. The ACCP/SCCM Consensus
Conference Committee. American College of Chest
Physicians/Society of Critical Care Medicine. Chest.
;101(6):1644-55.
Remick DG. Biological perspectives: Pathophysiology
of sepsis. Am J Pathol. 2007;170(5):1435-44.
Varghese JM, Roberts JA, Lipman J. Antimicrobial
pharmacokinetic and pharmacodynamic issues in the
critically ill with severe sepsis and septic shock. Crit
Care Clin. 2011;27:19-34.
McKindley DS, Hanes S, Boucher BA. Hepatic drug
metabolism in critical illness. Pharmacotherapy.
;18(4):759-78.
Spapen H. Liver perfusion in sepsis, septic shock and
multiorgan failure. Anat Rec. 2008;291:714-20.
Schumer W. Pathophysiology and treatment of septic
shock. Am J Emerg Med. 1984;2(1):74-7.
Lee WL, Slutsky AS. Sepsis and endothelial permeability. N Engl J Med. 2010;363(7):689-91.
Fleck A, Hawker F, Wallace PI, Raines G, Trotter J,
Ledingham IMCA, et al. Increased vascular permeability:
A major cause of hypoalbuminaemia in disease and
injury. Lancet. 1985;781-3.
Pea F, Viale P. Bench-to-bedside review: Appropriate
antibiotic therapy in severe sepsis and septic shock - does
the dose matter? Crit Care. 2009;3(3):1-13.
Smith BS, Yogaratnam D, Levasseur-Franklin KE, Forni
A, Fong J. Introduction to drug pharmacokinetics in
the critically ill patient. Chest. 2012;141(5):1327-33.
Blot SI, Pea F, Lipman J. The effect of pathophysiology
on pharmacokinetics in the critically ill patient:
Concepts appraised by the example of antimicrobial
agents. Adv Drug Deliv Rev. 2014;77:3-11.
Hosein S, Udy AA, Lipman J. Physiological changes
in the critically ill patient with sepsis. Curr Pharm
Biotechnol. 2011;12:1991-5.
Paepe P, Belpaire FM, Buylaert WA. Considerations
when treating patients with sepsis and septic shock.
Clin Pharmacokinet. 2002;41(14):1135-51.
Cone EJ, Fant RV, Henningfield JE. Nicotine and tobacco. In: Mozayani A, Raymond L, editors. Handbook of drug interactions: A clinical and forensic guide. New York: Humana Press; 2012.
Fraser AG. Pharmacokinetic interactions between
alcohol and other drugs. Clin Pharmacokinet.
;33(2):79-90.
Lane EA, Guthrie S, Linnoila M. Effects of ethanol
on drug and metabolite pharmacokinetics. Clin
Pharmacokinet. 1985;10:228-47.
Anderson GD, Chan LN. Pharmacokinetic drug
interactions with tobacco, cannabinoids and smoking
cessation products. Clin Pharmacokinet. 2016;1-16.
Miller LG. Cigarettes and drug therapy: pharmacokinetic
and pharmacodynamic considerations. Clin Pharm.
;9(2):125-35.
Silva WM, Dodt RCM, Carvalho REFL, Nogueira AO,
Farias LGO, Chaves EMC. Implications of antibacterial
scheduling in newborns in clinical nursing practice. Rev
Rene. 2015;16(6):809-16.
Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada
S, Yago K. Population pharmacokinetics of arbekacin,
vancomycin, and panipenem in neonates. Antimicrob.
Agents Chemother. 2004;48(4):1159-67.
Catão MHCV, Xavier AFC, Pinto TCAP. O impacto das
alterações do sistema eletromagnético na nutrição do
idoso. Rev Bras Ciênc Saúde. 2011;9(29):73-8.
Moreira IPB, Amado LEB, Bersani ALF, Bersani-Amado
CA, Caparroz-Assef SM. Principais aspectos do tratamento
das infecções no idoso. Ciênc Cuid Saúde.
;6(s2):488-95.
Wynne HA, Blagburn J. Drug treatment in an ageing
population: Pratical implications. Maturitas. 2010;
:246-50.
Medico CJ, Walsh P. Pharmacotherapy in the critically
ill obese patient. Crit Care Clin. 2010;26:679-88.
Wojcicki J, Jaroszynska M, Drozdzik M, Pawlik
A, Gawronska-Szklarz B, Sterna R. Comparative
pharmacokinetics and pharmacodynamics of
propranolol and atenolol in normolipaemic and
hyperlipidaemic obese subjects. Biopharm Drug Dispos.
;24:211-18.
Wolfgang AR, Kearns GL. Handbook of Basic
Pharmacokinetics. 7th ed. Washington, DC: American
Pharmacists Association; 2009.
Rodighiero V. Effects of liver disease on pharmacokinetics:
An update. Clin Pharmacokinet. 1999;37(5):399-431.
Stein IH, Kunihiro M, Yingying SMS. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308(22):2349-60.
Lorenzen JM, Broll M, Kaever V, Burhenne H, Hafer
C, Clajus C, et al. Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis. Clin J Am Soc Nephrol. 2012;7:385-90.
Sá Del Fiol F, Silva A. Uso de tetraciclinas durante a
gestação. Ciênc Biol Saúde. 2005;7(1):55-8.
Agência Nacional de Vigilância Sanitária. Uso de
antimicrobianos em populações especiais. Brasília:
ANVISA; 2008 [citado 10 de out. 2016]. Disponível
em: http://www.anvisa.gov.br/servicosaude/controle/
rede_rm/cursos/atm_racional/modulo4/introducao.htm
Chaves RG, Lamounier JA, César CC. Medicamentos e
amamentação: atualização e revisão aplicadas à clínica
materno-infantil. Rev Paul Pediatr. 2007;25(3):276-88.
Reali A, Ximenes A, Cuzzolin L, Fanos V. Antibiotic
therapy in pregnancy and lactation. J Chemother.
;17(2):123-30.
Joukhadar C, Frossard M, Mayer B, Brunner M,
Klein N, Siostrzonek P, et al. Impaired target site
penetration of β-lactams may account for therapeutic
failure in patients with septic shock. Crit Care Med.
;29(2):385-91.
Marik PE. Aminoglycoside volume of distribution and
illness severity in critically ill septic patients. Anaesth
Intensive Care. 1993;21(2):172-83.
Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong
Ely, Gin T. The pharmacokinetics of once-daily dosing
of ceftriaxone in critically ill patients. J Antimicrob
Chemother. 2001;47:421-9.
Ulldemolins M, Roberts JA, Wallis SC, Rello J,
Lipman J. Flucloxacillin dosing in critically ill patients
with hypoalbuminaemia: Special emphasis on
unbound pharmacokinetics. J Antimicrob Chemother.
;65:1771-8.
Ulldemolins M, Rello J. The relevance of drug volume
of distribution in antibiotic dosing. Current Pharm
Biotechnol. 2011;12:1996-2001.
Campassi ML, Gonzalez MC, Masevicius FD.
Augmented renal clearance in critically ill patients:
Incidence, associated factors and effects on vancomycin
treatment. Rev Bras Ter Intensiva. 2014;26(1):13-20.
Roberts JA, Aziz MHA, Lipman J, Mouton JW, Vinks A,
Felton TW, et al. Challenges and potential solutions:
Individualised antibiotic dosing at the bedside for
critically ill patients: a structured review. Lancet Infect
Dis. 2014;14(6):498-509.
Pea F. Plasma pharmacokinetics of antimicrobial agents
in critically ill patients. Curr Clin Pharmacol. 2013;8:5-12.
World Health Organization. Global status report on
alcohol and health 2014. Geneva: WHO; 2014 [cited
Oct 16]. Available from: http://apps.who.int/iris/
bitstream/10665/112736/1/9789240692763_eng.
pdf?ua=1
Laranjeira R, Madruga CS, Pinsky I, Caetano R,
Mitsuhiro SS. Segundo Levantamento Nacional de
Álcool e Drogas (LENAD): relatório 2012. São Paulo:
INPAD; 2014.
Souza-Smith FM, Lang CH, Nagy LE. Physiological
processes underlying organ injury in alcohol abuse.
Am J Physiol Endocrinol Metab. 2016;311:605-19.
Franke A, Teyssen S, Harder H, Singer MV. Effect of
ethanol and some alcoholic beverages on gastric
emptying in humans. Scand J Gastroenterol.
;7:638-44.
Bujanda L. The effects of alcohol consumption
upon the gastrointestinal tract. Am J Gastroenterol.
;95(12):3374-82.
Chan LN, Anderson GD. Pharmacokinetic and
pharmacodynamic drug interactions with ethanol
(alcohol). Clin Pharmacokinet. 2014;53(12):1115-36.
Lindberg RL, Huupponen RK, Viljanen S, Pihlajamäki KK. Ethanol and the absorption of oral penicillin in man.
Int J Clin Pharmacol Ther Toxicol. 1987;25(10):536-48.
Morasso MI, Hip A, Márquez M, González C, Arancibia
A. Amoxicillin kinetics and etanol ingestion. Int J Clin
Pharmacol Ther Toxicol. 1988;26(9):428-31.
Kamali F. No influence of ciprofloxacin on ethanol
disposition: A pharmacokinetic-pharmacodynamic interaction study. Eur J Clin Pharmacol. 1994;47(1):71-4.
Morasso MI, Chávez J, Gai MN, Arancibia A. Influence of alcohol consumption on erythromycin ethylsuccinate kinetics. Int J Clin Pharmacol Ther Toxicol. 1990;8(10):426-9.
Seitz C, Garcia P, Arancibia A. Influence of ethanol
ingestion on tetracycline kinetics. Int J Clin Pharmacol
Ther. 1995;33(8):462-4.
World Health Organization. Tobacco health topic.
Geneva: WHO; 2016 [cited 2016 Oct 19]. Available
from: http://www.who.int/topics/tobacco/en
World Health Organization. Global health observatory
data: Prevalence of tobacco use. Geneva: WHO; 2015
[cited 2016 Nov 20]. Available from: http://www.who.
int/gho/tobacco/use/en
World Health Organization. Global report on trends in
prevalence of tobacco smoking. Geneva: WHO; 2015
[cited 2016 Oct 19]. Available from: http://www.who.
int/gho/tobacco/use/en
Scollo MM, Winstanley MH. Tobacco in Australia:
Facts and issues. Melbourne: Cancer Council Victoria;
[cited 2016 Oct 20]. Available from: www.
tobaccoinaustralia.org.au
Thomas GAO, Rhodes J, Ingram JR. Mechanisms of
disease: Nicotine - a review of its actions in the context
of gastrointestinal disease. Nat Clin Pract Gastroenterol
Hepatol. 2005;2(11):536-44.
Gritz ER, Ippoliti A, Jarvik ME, Rose JE, Shiffman S,
Harrison A, et al. The effect of nicotine on the delay of
gastric emptying. Aliment Pharmacol. 1988;2:173-8.
Cone EJ, Fant RV, Henningfield JE. Nicotine and tobacco. In: Mozayani A, Raymond L, editors. Handbook of drug interactions: A clinical and forensic guide. New Jersey: Humana Press; 2004.
Zevin S, Benowitz NL. Drug interactions with tobacco smoking: An update. Clin Pharmacokinet. 1999;36(6):425-38.
Turrini RNT. Infecção hospitalar e mortalidade. Rev Esc
Enferm. 2002;36(2):177-83.
Nagata E, Brito ASJ, Matsuo T. Nosocomial infections
in a neonatal intensive care unit: Incidence and risk actors. Am J Infect Control. 2002;30(1):26-30.
Silva ND, Vieira MRR. A atuação da equipe de enfermagem na assistência ao recém-nascido de risco em um hospital de ensino. Arq Ciênc Saúde. 2008;15(3):110-6.
Martins CP, Tapia CEV. A pele do recém-nascido prematuro sob a avaliação do enfermeiro: cuidado norteando a manutenção da integridade cutânea. Rev
Bras Enferm. 2009;62(5):778-83.
Scheuplein R, Charnley G, Dourson M. Differential sensitivity of children and adults to chemical toxicity. Regul Toxicol Pharmacol. 2002;35:429-47.
Aigrain EJ, Zhao W, Sharland M, Van Den Anker JN.
Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Semin Fetal Neonatal Med. 2013;18:28-34.
Machado JKK, Feferbaum R, Kobayashi CE, Sanches
C, Santos SRCJ. Vancomycin pharmacokinetics in preterm infants. Clinics. 2007;62(4):405-10.
Rocha MJ, Almeida AM, Afonso E, Martins V, Leitão
F, Santos J, et al. Recém-nascidos e monitorização sérica de gentamicina. Acta Méd Port. 2003;16:389-94.
Sousa KC, Pinto ACG, Silva MV, Soler O, Cuentro V, Andrade M. Tendências de prescrição de antimicrobianos em idosos hospitalizados em um hospital universitário. Rev Saúde Pesqui. 2015;8(3):501-8.
Rajagopalan S, Yoshikawa TT. Antimicrobial therapy in the elderly. Med Clin North America. 2001;85(1):133-47.
Her r ing AR, Wi l liamson JC. Pr inciples of ntimicrobial use in older adults. Clin Geriatr Med. 2007;23(3):481-97.
World Health Organization. Obesity and overweight.
Geneva: WHO; 2016 [cited 2016 Nov 10]. Available
from: http://www.who.int/mediacentre/factsheets/fs311/en/
Hanley MJ, Abernetthy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;9(2):71-87.
Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci. 1999;88:1-7.
World Health Organization Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157-63.
Green B, Duffull SB. What is the best size descriptor
to use for pharmacokinetic studies in the obese? Br J Pharmacol. 2004;52(8):119-33.
Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing
in obese patients. Clin Infect Dis. 1997;25(1):112-8.
Bearden DB, Rodvold KA. Dosage adjustments for antibacterials in obese patients: Applying clinical pharmacokinetics. Clin Pharmacokinet. 2000;38(5):415-426.
Allard S, Kinzig M, Boivin G, Sorgel F, LeBel M. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther. 1993;54(4):368-73.
Janson B, Thursky K. Dosing of antibiotics in obesity.
Curr Opin Infect Dis. 2012;25(6):634-49. http://dx.doi.org/10.1097/QCO.0b013e328359a4c1
Genser D. Food and drug interaction: Consequences
for the nutrition/health status. Ann Nutr Metab. 2008;52(1):29-32.
Gura KM. Antibiotics and drugs: Drug-nutrient interactions. In: Caballero B, Finglas P, Toldra F. Encyclopedia of Food and Health. Amsterdam: Academic Press; 2015. p.174-91.
Lopes EM, Oliveira EAR, Lima LHO, Formiga LMF, retas MF. Interações fármaco-alimento/nutriente potenciais em pacientes pediátricos hospitalizados. Rev Ciênc Farm Básica Apl. 2013;34(1):131-5.
Moura MRL, Reyes FGR. Interação fármaco-nutriente:
uma revisão. Rev Nutr. 2002;15(2):223-38.
Bobroff LB, Lentz A, Turner RE. Food/drug and drug/
nutrient interactions: What you should know about your medications. Florida: University of Florida; 2009.
Gonzalez TP, Schiengold M, Chies JAB. Implicações clínicas dos polimorfismos do gene de resistência a múltiplas drogas MDR1 (ABCB1). Rev Bras Biociênc. 2006;4(3/4):27-38.
Gracia BH, Ambrosio EP, Della-Rosa VA. O polimorfismo dos genes cyp2c9 e vkorc1 e suas influências na ação anticoagulante da varfarina. Rev Saúde Biol. 2014;9(2):93-103.
Autrup H. Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. Mutat Res. 2000;464:65-76.
Norton RM. Clinical Pharmacogenomics: Aplications in pharmaceutical R & D. Drug Discov Today. 2001;6(4):180-5.
Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: Na opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999;20:342-9.
Klein K, Zanger UM. Pharmacogenomics of cytochrome P450 3A4: Recent progress toward the “missing heritability” problem. Front Genetics. 2013;4:1-15.
Micromedex® Healthcare Series. Greenwood Village:
Thomson Healthcare [cited 2017 Jan 11]. Available from: http://www-micromedexsolutionscom.ez32.periodicos.capes.gov.br/micromedex2/librarian
Dean M, Rzhetsky A, Allikmets R. The human ATPBinding Cassette (ABC) Transporter Superfamily. Genome Res. 2001;11:1156-66.
Weinstein JR, Sharaon MD. Aging Kidney: Physiological changes. Adv Chronic Kidney Dis. 2010;17(4):302-7.
Ministério da Saúde. Diretrizes clínicas para o cuidado ao paciente com doença renal crônica: DRC no sistema único de saúde. Brasília; 2014 [citado 2017 jan 15]. Disponível em: http://sonerj.org.br/wp-content/uploads/2014/03/diretriz-cl-nica-drcversao-
final2.pdf
Bouman CSC. Antimicrobial dosing strategies in critically ill patients with acute kidney injury and high-dosecontinuous veno-venous hemofiltration. Curr Opin Crit Care. 2009;14:654-9.
Zamoner W, Freitas FM, Garms DSS, De Oliveira
MG, Balbi AL, Ponce D. Pharmacokinetics and pharmacodynamics of antibiotics in critically ill acute kidney injury patients. Pharmacol Res Perspect. 2016;4(6):5.
Blot S, Lipman J, Roberts DM, et al. The influence of acute kidney injury on antimicrobial dosing in critically ill patients: Are dose reductions always necessary? Diagn Microbiol Infect Dis, 2014;79:77-84.
Brown JR, Parikh CR, Ross CS, Kramer RS, Magnus PC, Chaisson K, et al. Impact of perioperative acute kidney injury as a severity index for thirty-day readmission after cardiac surgery. Ann Thorac Surg.2014;97(1):111-7.
Gilbert DN, Chambers HF, Eliopoulos GM, Sande MA.
The Sanford Guide to Antimicrobial Therapy. 44th ed. Dallas: Antimicrobial Therapy; 2014.
Mushatt DM, Mihm LB, Dreisbach AW, Simon EE. Antibiotic dosing in slow extended daily dialysis. Clin Infect Dis. 2009;49:433-7.
Petejova N, Martinek A, Zahalkova J, Duricova J, Brozmanova H, Urbanek K, et al. Vancomycin removal during low-flux and high-flux extended daily hemodialysis in critically ill septic patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012;156(4): 342-7.
Bogard KN, Peterson NT, Plumb TJ. Antibiotic dosing
during sustained low-efficiency dialysis: Special considerations in adult critically ill patients. Crit Care Med. 2011;39(3):560-70.
Eyler RF, Mueller BA. Antibiotic dosing in critically ill
patients with acute kidney injury. Nat Rev Nephrol. 2011;7:226-35.
Beumier M, Casu GS, Hites M, Seyler L, Cotton F, Vincent JL, et al. β-lactam antibiotic concentrations during continuous renal replacement therapy. Crit Care. 2014;18:10.
Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P,
Cole L, et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: A multicenter pharmacokinetic study. Crit Care Med. 2012;40(5):1523-8.
Malone RS, Fish DN, Abraham E, Teitelbaum I. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother. 2001;45(11):3148-55.
Carlier M, Tacconec FS, Beumierc M, Seyler L, Cotton
F, Jacobs F, et al. Population pharmacokinetics and dosing simulations of cefepime inseptic shock patients receiving continuous renal replacement therapy. IntJ Antimicrob Agents. 2015;46(4):413-9.
Thalhammer F, Hörl WH. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement. Ther Clin Pharmacokinet. 2000;39(4):271-9.
Deshpande P, Chen J, Gofran A. Meropenem removal
in critically ill patients undergoing sustained lowefficiency
dialysis (SLED). Nephrol Dial Transplant. 2010;25:2632-6.
Newsome BB, Warnock DG, McClellan WM, Herzog CA, Kiefe CI, Eggers PW, et al. Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med. 2008;168:609-16.
Rybak MJ. The pharmacokinetic and pharmacodynamic
properties of vancomycin. Clin Infect Dis.2006;4(S1):S35-9.
Benedetti MS, Whomsley R, Poggesi I, Cawello W, Math FX, Delporte ML, et al. Drug metabolism and pharmacokinetics. Drug Metab Rev. 2009;41(3):344-90.
Mehrotra R, Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med. 2004;30:2145-56.
Oettl K, Birner-Gruenberger R, Spindelboeck W. Oxidative albumin damage in chronic liver failure: Relation to albumin binding capacity, liver dysfunction and survival. J Hepatol. 2013;59:978-83.
Terada T, Hira D. Intestinal and hepatic drug transporters: Pharmacokinetic, pathophysiological, and pharmacogenetic roles. J Gastroenterol. 2015;50:508-19.
Poggesi I, Benedetti MS, Whomsley R, Le Lamer S, Molimard M, Watelet JB. Pharmacokinetics in special populations. Drug Metabolism. 2009;41(3):422-54.
Almazroo OM, Miah MK, Venkataramanan R. Drug
metabolism in the liver. Clin Liver Dis. 2017;21(1):1-20.
Wolfgang A, Kearns GL, Handbook of basic pharmacokinetics. 7th ed. American Pharmacists Association; 2009.
Delco F, Tchambaz L, Schlienger R, Drewe J, Krähenbühl S. Dose adjustment in patients with liver disease. Drug Safety. 2005;28(6):529-45.
Gomes KRO, Moron AF, Silva RS, Siqueira AAF. Prevalência do uso de medicamentos na gravidez e relações com as características maternas. Rev Saúde Pública. 1999;33(3):246-54.
Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: What is and is not known about teratogenic and toxic risks. Obst Gynecol. 2006;107(5):1120-38.
Rodrigues AVP, Terrengui LCS. Uso de medicamentos
durante a gravidez. Rev Enferm. 2006;7:9-14.
Feghali MN, Mattison, DR. Clinical therapeutics in pregnancy. J Biomed Biotechnol. 2011;1-13.
Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014;5:1-5.
Kulay Junior L, Lapa AJ, editores. Drogas na gravidez:
manual de orientação. São Paulo: Ponto; 2003.
Nordeng S, Nordeng H, Hoye S. Bruk av antibiotika i svangerskapet. Tidsskr Nor Legeforen. 2016;136(4):317-21.
Vallano A, Arnau JM. Antimicrobianos y embarazo. Enferm Infecc Microbiol Clin. 2009;27(9):536-42.
Norwitz ER, Greenberg JA. Antibiotics in Pregnancy:
Are They Safe? Rev Obstet Gynecol. 2009;2(3):135-6.
Marks JM, Spatz DL. Medications and lactation: What PNPs need to know. J Pediatr Health Care. 2003;17:311-7.
Chaves RG, Lamounier JA. Uso de medicamentos durante a lactação. J Pediatr. 2004;80(S5):S189-98.
Hale TW. Medications and mother’s milk. 12th ed. Amarillo: Pharmasoft Publishing; 2006.
World Health Organization. Cardiovascular Diseases:
Fact sheet (317). Geneva: WHO; 2015 [cited 2017 Mar 20]. Available from: http://www.who.int/mediacentre/factsheets/fs317/en
Souza CSM, Pires CN, Rocha RM. Insuficiência cardíaca
aguda. Rev Hosp Univ Pedro Ernesto. 2009;8(2):58-66.
Maciver DH, Dayer MJ, Harrison AJ. A general theory
of acute and chronic heart failure. Int J Cardiol. 2013;165:25-34.
Barretto ACP, Ramires JAF. Insuficiência cardíaca. Arq
Bras Cardiol. 1998;71(4):635-42.
Shammas FV, Dickstein K. Clinical pharmacokinetics in
heart failure: An updated review. Clin Pharmacokinet. 1988;15(2):94-113.
Ueda CT, Dzindzio BS. Bioavailabi l ity of quinidine in congestive heart failure. Br J Clin Pharmac.1981;11:571-7.
Pentel P, Benowitz N. Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies. Clin Pharmacokinet. 1984;9:273-308.
